Evidence map›Paper›PMID 38910424›Full record

ArticleCNS & neurological disorders drug targets2025

Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series.

Giovanni Di Mauro, Giovanni Vietri, Loreta Quaranta, Fabio Placidi, Francesca Izzi, Alessandro Castelli, Andrea Pagano, Francesca Leonardis, Viviana De Angelis, Ciro Bianco and 3 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in CNS & neurological disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Giovanni Di MauroEpilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.ORCID 0000-0002-2359-381X
Giovanni VietriDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Loreta QuarantaDivision of Neurology and Stroke Unit, Epilepsy Centre, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy.
Fabio PlacidiEpilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Francesca IzziEpilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Alessandro CastelliEpilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Andrea PaganoEpilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
Francesca LeonardisDepartment of Clinical Sciences and Translational Medicine, Intensive Care Unit, University of Rome 'Tor Vergata', Rome, Italy.
Viviana De AngelisDepartment of Clinical Sciences and Translational Medicine, Intensive Care Unit, University of Rome 'Tor Vergata', Rome, Italy.
Ciro BiancoClinical Pharmacy, University Hospital of Rome "Tor Vergata", Rome, Italy.
Maria Grazia CelesteClinical Pharmacy, University Hospital of Rome "Tor Vergata", Rome, Italy.
Nicola Biagio MercuriDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Claudio LiguoriEpilepsy Centre, Neurology Unit, University Hospital Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRefractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment for these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex. CASE PRESENTATION: Here, we present two cases of effective use of hpCBD in both refractory and super- refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures.

conclusionAccording to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.

Indexed as

AnticonvulsantsCannabidiolDrug Resistant EpilepsyStatus EpilepticusHumansTreatment OutcomeAnticonvulsantsCannabidiolanti-seizure medicationemergencyepilepsylennox-gastaut syndrome.seizureStatus epilepticus

Identifiers

PMID38910424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.